This article is for general information only and is not a substitute for professional medical advice. Do not stop, start, or change any medication based on what you read here. See our full medical disclaimer.

GLP-1 receptor agonists produce some of the largest sustained weight losses ever recorded in pharmaceutical trials. A question that follows many patients: how much of that lost weight is fat, and how much is the muscle needed for strength, metabolism, and long-term health?

The direct answer: GLP-1 drugs do cause some lean mass loss. The STEP 1 body composition substudy using DEXA found that total lean body mass fell about 9.7 percent in absolute terms over 68 weeks on semaglutide 2.4 mg weekly, while fat mass fell at 19.3 percent. The drugs do not selectively attack muscle, but losing lean tissue on top of age-related decline can push some people closer to functional problems.

Key Takeaways

  • In the STEP 1 DEXA substudy, semaglutide users lost 5.26 kg of lean mass alongside 8.36 kg of fat mass over 68 weeks.
  • A 2024 review found lean mass accounts for roughly 25 to 40 percent of total weight lost across GLP-1 trials.
  • Body composition ratios still improve because fat loss outpaces lean loss, but absolute muscle loss is real.
  • Older adults, women, and people with low protein intake face the highest risk of clinically significant muscle loss.
  • Resistance training two to three times per week plus at least 1.2 g protein per kg body weight per day are the two best-supported countermeasures.
  • The Phase 2b BELIEVE trial showed bimagrumab plus semaglutide achieved 92.8 percent fat-only weight loss, though this combination is not yet approved.

What the STEP Trials Found About Body Composition

The STEP 1 exploratory DEXA substudy followed 1,961 adults randomized to subcutaneous semaglutide 2.4 mg once weekly or placebo for 68 weeks. Participants on semaglutide lost 15.0 percent of body weight versus 3.6 percent on placebo. The semaglutide group lost 8.36 kg of fat mass and 5.26 kg of lean mass; the placebo group lost 1.37 kg of fat and 1.83 kg of lean mass.

The lean-to-fat ratio actually improved with semaglutide: it rose by 0.23 from a baseline of 1.34. Among participants who lost at least 15 percent of body weight, that ratio improved by 0.41. The body composition shift was favorable even though some muscle was lost in absolute terms. The SEMALEAN study added a useful data point: lean mass declined about 3 kg by month 7 then stabilized through month 12, while fat mass kept falling.

How GLP-1 Muscle Loss Compares to Regular Dieting

GLP-1 medications do not do anything uniquely destructive to muscle. Every caloric deficit causes some lean tissue loss. The standard benchmark in the weight loss literature is that roughly 20 to 30 percent of weight lost through diet-only interventions comes from lean tissue. A 2024 review and meta-analysis in Diabetes, Obesity and Metabolism found GLP-1 receptor agonists reduced lean mass by approximately 25 percent relative to total weight lost, with individual study figures ranging from 15 to 40 percent depending on age, exercise habits, and protein intake.

What distinguishes GLP-1 therapy is scale. These drugs achieve 15 to 22 percent body weight reductions that previously required bariatric surgery. A person losing 30 pounds on semaglutide might lose 7 to 12 pounds of that from lean mass. The percentage breakdown is comparable to conventional dieting; the absolute amount is larger because the total loss is larger. For a full picture of how these medications work, see our explainer on GLP-1 medications.

Why Muscle Loss Matters and Who Is Most at Risk

Skeletal muscle drives resting metabolic rate, glucose disposal, and functional independence. For younger adults with adequate lean mass reserves, losing a few kilograms of muscle during a major weight loss effort is unlikely to cause noticeable functional decline. For adults over 65, the math is less forgiving.

Natural aging already reduces skeletal muscle mass by roughly 12 to 16 percent, according to a 2024 Endocrine Society review. Half of adults over 80 have clinically significant sarcopenia, the term for low muscle mass and strength. An editorial in the Annals of Internal Medicine flagged that GLP-1 receptor agonists are being prescribed to older adults who may lack the reserve to absorb pharmacologically induced muscle losses without functional consequences. A study at ENDO 2025 added a metabolic dimension: semaglutide users who lost more muscle showed less improvement in HbA1c than those who preserved lean mass.

The Endocrine Society study also identified three characteristics linked to greater muscle loss after controlling for total weight lost: older age, female sex, and inadequate protein intake. Sedentary GLP-1 users face compounded risk because appetite suppression can reduce both total calories and protein intake simultaneously. For a broader look at adverse effects on this drug class, see our summary of Ozempic side effects.

How to Protect Muscle While on a GLP-1 Drug

Lean mass loss during GLP-1 treatment is not inevitable at levels that impair function. Two strategies have solid clinical backing.

Resistance Training

Resistance training is the most effective tool for preserving muscle during weight loss. A 6-month study of 200 adults who started semaglutide or tirzepatide alongside structured resistance exercise and protein guidance lost about 13 percent of body weight but only about 3 percent of muscle mass. That ratio is substantially better than what the STEP trials observed without structured exercise. Two to three sessions per week targeting major muscle groups is the evidence-based minimum; bodyweight training works when gym access is limited.

Adequate Protein Intake

The standard RDA of 0.8 g of protein per kg of body weight per day was set to prevent deficiency in sedentary adults, not to preserve muscle during weight loss. A 2022 systematic review and meta-analysis found that intakes of 1.2 to 1.6 g per kg per day preserved lean mass and strength during caloric restriction across age groups. Endocrine Society guidance now commonly targets at least 1.2 g per kg per day for GLP-1 users, with some clinicians recommending 1.5 g per kg for older adults.

Because these drugs suppress appetite substantially, protein intake can fall disproportionately if overall food volume drops. Distributing protein across three to four meals rather than eating the same total amount in one or two sittings is more effective for muscle protein synthesis. Working with a registered dietitian can help calibrate intake without triggering severe caloric restriction, which independently accelerates lean mass loss.

Emerging Research: Bimagrumab Combinations

The pharmaceutical pipeline includes drug combinations designed to decouple fat loss from lean mass loss. The Phase 2b BELIEVE trial, published in Nature Medicine in 2026, tested bimagrumab (a monoclonal antibody that blocks muscle breakdown signaling) combined with semaglutide. The combination achieved 22.1 percent total weight loss over 72 weeks. Critically, 92.8 percent of that weight loss came from fat mass, compared to 71.8 percent in the semaglutide-alone group. Bimagrumab is not approved as of mid-2026, but the trial demonstrates that near-total fat-specific weight loss is biologically achievable.

Actionable Steps: Protecting Lean Mass on GLP-1 Treatment

  1. Start resistance training at the same time as the medication, not after lean mass loss has already occurred. Two to three sessions per week is the minimum.
  2. Track daily protein explicitly. Aim for at least 1.2 g per kg of body weight. A one-week food log establishes your baseline.
  3. Spread protein across three to four meals. Muscle protein synthesis responds better to distributed intake than to one large protein dose per day.
  4. Do not over-restrict calories. If nausea limits eating, prioritize protein-dense foods first when appetite returns. Severe restriction accelerates muscle loss independently of protein percentage.
  5. Request a baseline assessment if you are over 55 or have a history of low physical activity. A starting measure of muscle mass or grip strength gives you a benchmark for monitoring during treatment.

Frequently Asked Questions

Do GLP-1 drugs like semaglutide cause muscle loss?

Yes, some lean mass loss is expected with any significant weight loss, and GLP-1 drugs are no exception. The STEP 1 DEXA substudy found lean body mass declined about 9.7 percent in absolute terms over 68 weeks on semaglutide 2.4 mg. Fat mass fell faster at 19.3 percent, so the body composition ratio improved. The concern centers on the absolute amount of muscle lost, particularly for older adults with less reserve.

How much of weight lost on a GLP-1 drug is actually muscle?

A 2024 review in Diabetes, Obesity and Metabolism found lean mass loss accounted for roughly 25 percent of total weight lost across GLP-1 receptor agonist trials on average. Individual study figures range from 15 to 40 percent depending on patient age, baseline muscle mass, protein intake, and exercise habits during treatment.

Is GLP-1 muscle loss worse than muscle loss from regular dieting?

Not in percentage terms. Standard diet-only interventions also lose 20 to 30 percent of weight from lean tissue. GLP-1 therapies fall in a comparable range. The difference is the larger total weight loss these drugs achieve, which means the absolute pounds of muscle lost can be higher even if the proportion is similar.

What can I do to protect muscle while taking a GLP-1 medication?

Resistance training two to three times per week and consuming at least 1.2 g of protein per kg of body weight per day are the two best-supported strategies. A 6-month study presented at ENDO 2025 found that adults who received guidance on both at the start of semaglutide or tirzepatide treatment lost about 13 percent of body weight but only about 3 percent of muscle mass. Always discuss diet and exercise changes with your prescribing clinician before making them.

Sources

  • Wadden TA, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021. PMC8089287.
  • Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024. PubMed 38937282.
  • Haines MS. Protein intake and muscle loss in semaglutide users. Presented at ENDO 2025; Endocrine Society Annual Meeting.
  • Bimagrumab + Semaglutide BELIEVE trial. Nature Medicine. 2026. Via EurekAlert.
  • Morton RW, et al. Systematic review and meta-analysis of protein intake to support muscle mass and function in healthy adults. Nutr Rev. 2022. PMC8978023.

Sources